The stock price of Neogenomics Inc (NASDAQ: NEO) has surged by 8.67 when compared to previous closing price of 9.34, but the company has seen a -2.40% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-28 that NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company’s negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern.
Is It Worth Investing in Neogenomics Inc (NASDAQ: NEO) Right Now?
Additionally, the 36-month beta value for NEO is 1.43. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for NEO is 126.92M and currently, short sellers hold a 2.71% ratio of that float. The average trading volume of NEO on March 06, 2025 was 1.06M shares.
NEO’s Market Performance
The stock of Neogenomics Inc (NEO) has seen a -2.40% decrease in the past week, with a -26.87% drop in the past month, and a -42.75% fall in the past quarter. The volatility ratio for the week is 7.04%, and the volatility levels for the past 30 days are at 6.95% for NEO. The simple moving average for the last 20 days is -15.26% for NEO stock, with a simple moving average of -31.82% for the last 200 days.
Analysts’ Opinion of NEO
Jefferies, on the other hand, stated in their research note that they expect to see NEO reach a price target of $22. The rating they have provided for NEO stocks is “Buy” according to the report published on December 10th, 2024.
Craig Hallum gave a rating of “Buy” to NEO, setting the target price at $26 in the report published on May 01st of the previous year.
NEO Trading at -28.08% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.90% of loss for the given period.
Volatility was left at 6.95%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -27.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.45% lower at present.
During the last 5 trading sessions, NEO fell by -2.40%, which changed the moving average for the period of 200-days by -32.91% in comparison to the 20-day moving average, which settled at $11.98. In addition, Neogenomics Inc saw -38.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NEO starting from Olivo Alicia C, who sale 5,175 shares at the price of $15.36 back on Nov 15 ’24. After this action, Olivo Alicia C now owns 37,129 shares of Neogenomics Inc, valued at $79,475 using the latest closing price.
ALICIA OLIVO, the Officer of Neogenomics Inc, proposed sale 5,175 shares at $15.79 during a trade that took place back on Nov 15 ’24, which means that ALICIA OLIVO is holding shares at $81,713 based on the most recent closing price.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.43 for the gross margin
The net margin for Neogenomics Inc stands at -0.12. The total capital return value is set at -0.07. Equity return is now at value -8.54, with -4.74 for asset returns.
Based on Neogenomics Inc (NEO), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.01. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is -13.32.
Currently, EBITDA for the company is -1.51 million with net debt to EBITDA at -157.72. When we switch over and look at the enterprise to sales, we see a ratio of 2.33. The receivables turnover for the company is 4.39for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
In conclusion, Neogenomics Inc (NEO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
